Nalaganje...
CFTR Modulators for the Treatment of Cystic Fibrosis
Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MediMedia USA, Inc.
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4103577/ https://ncbi.nlm.nih.gov/pubmed/25083129 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|